A Randomized, Double-Blind, Placebo-Controlled, Phase II Study of MBG453 Added to Hypomethylating Agents (HMAs) in Patients (pts) with Intermediate, High, or Very High Risk Myelodysplastic Syndrome (MDS): Stimulus-MDS1

被引：5
|
作者：
Zeidan, Amer M. [1 ,2 ]
Miyazaki, Yasushi [3 ]
Platzbecker, Uwe [4 ]
Malek, Kamel [5 ]
Niolat, Julie [6 ]
Kiertsman, Flavia [7 ]
Fenaux, Pierre [8 ]
机构：
[1] Yale Univ, East Haven, CT USA
[2] Yale Canc Ctr, East Haven, CT USA
[3] Nagasaki Univ Hosp, Atom Bomb Dis Inst, Nagasaki, Japan
[4] Univ Hosp Leipzig, Leipzig, Germany
[5] Novartis Pharma AG, Basel, Switzerland
[6] Novartis Pharma SAS, Rueil Malmaison, France
[7] Novartis Pharmaceut, E Hanover, NJ USA
[8] Univ Paris Diderot, Hop St Louis, Paris, France
来源：
BLOOD | 2019年 / 134卷
关键词：
D O I：
10.1182/blood-2019-127041
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4259
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Primary Results of Stimulus-MDS1: A Randomized, Double-Blind, Placebo-Controlled Phase II Study of TIM-3 Inhibition with Sabatolimab Added to Hypomethylating Agents (HMAs) in Adult Patients with Higher-Risk Myelodysplastic Syndromes (MDS)
    Zeidan, Amer M.
    Ando, Kiyoshi
    Rauzy, Odile
    Turgut, Mehmet
    Wang, Ming-Chung
    Cairoli, Roberto
    Hou, Hsin-An
    Kwong, Yok-Lam
    Sangerman, Montserrat Arnan
    Meers, Stef
    Pullarkat, Vinod A.
    Santini, Valeria
    Malek, Kamel
    Kiertsman, Flavia
    Lyu, Jiaying
    Ramos, Pedro Marques
    Fenaux, Pierre
    Miyazaki, Yasushi
    Platzbecker, Uwe
    BLOOD, 2022, 140 : 2063 - 2065
  • [2] Sabatolimab in Combination with Hypomethylating Agents (HMAs) Was Safe in Patients (Pts) with Intermediate-, High-, or Very-High-Risk Myelodysplastic Syndrome (MDS)
    Garcia-Manero, Guillermo
    Lyons, Roger M.
    Nandal, Savita
    Ashraf, Mushtaq
    Thellaboina, Ramarao
    Ruckel-Kumar, Julie
    Menssen, Hans D.
    Zeidan, Amer M.
    BLOOD, 2023, 142
  • [3] Anti-TIM-3 Antibody MBG453 in Combination with Hypomethylating Agents (HMAs) in Patients with High-Risk Myelodysplastic Syndrome (HR-MDS) and Acute Myeloid Leukemia: A Phase 1 Study
    Brunner, Andrew
    Borate, Uma
    Esteve, Jordi
    Porkka, Kimmo
    Knapper, Steve
    Vey, Norbert
    Scholl, Sebastian
    Wermke, Martin
    Janssen, Jeroen
    Traer, Elie
    Chua, Chong Chyn
    Narayan, Rupa
    Tovar, Natalia
    Kontro, Mika
    Ottman, Oliver
    Xu, Siyan
    Sun, Haiying
    Naidu, Purushotham
    Szpakowski, Sebastian
    Zhang, Na
    Mohammed, Anisa
    Rinne, Mikael
    Wei, Andrew
    Garcia-Manero, Guillermo
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S188 - S189
  • [4] Sabatolimab plus hypomethylating agents in previously untreated patients with higher-risk myelodysplastic syndromes (STIMULUS-MDS1): a randomised, double-blind, placebo-controlled, phase 2 trial
    Zeidan, Amer M.
    Ando, Kiyoshi
    Rauzy, Odile
    Turgut, Mehmet
    Wang, Ming -Chung
    Cairoli, Roberto
    Hou, Hsin-An
    Kwong, Yok-Lam
    Arnan, Montserrat
    Meers, Stef
    Pullarkat, Vinod
    Santini, Valeria
    Malek, Kamel
    Kiertsman, Flavia
    Niolat, Julie
    Ramos, Pedro Marques
    Menssen, Hans D.
    Fenaux, Pierre
    Miyazaki, Yasushi
    Platzbecker, Uwe
    LANCET HAEMATOLOGY, 2024, 11 (01): : e38 - e50
  • [5] Stimulus MDS-US Trial in Progress: Evaluating Sabatolimab in Combination with Hypomethylating Agents (HMAs) in Patients with Intermediate-, High-, or Very High-Risk Myelodysplastic Syndrome (MDS)
    Zeidan, Amer M.
    DeZern, Amy E.
    Borate, Uma
    Kobata, Krissy
    Ide, Susan E.
    Sabo, John
    Ramos, Pedro Marques
    Sun, Haiying
    Lyons, Roger M.
    Garcia-Manero, Guillermo
    BLOOD, 2022, 140 : 4069 - 4070
  • [6] Efficacy and safety of sabatolimab (MBG453) in combination with hypomethylating drugs (HMAs) in patients with very high or high risk myelodysplastic syndrome (vHR/HR-MDS) and acute myeloid leukemia (AML): final analysis after a phase Ib study
    Brunner, A.
    Porkka, K.
    Knapper, S.
    Traer, E.
    Scholl, S.
    Garcia-Manero, G.
    Vey, N.
    Wermke, M.
    Janssen, J.
    Narayan, R.
    Loo, S.
    Tovar, N.
    Kontro, M.
    Naidu, P.
    Pelletier, M.
    Steensma, D.
    Lewandowski, A.
    Zhang, N.
    Mohammed, A.
    Borate, U.
    Wei, A.
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 35 - 36
  • [7] Efficacy and Safety of Sabatolimab (MBG453) in Combination with Hypomethylating Agents (HMAs) in Patients with Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (HR-MDS): Updated Results from a Phase 1b Study
    Brunner, Andrew M.
    Esteve, Jordi
    Porkka, Kimmo
    Knapper, Steve
    Vey, Norbert
    Scholl, Sebastian
    Garcia-Manero, Guillermo
    Wermke, Martin
    Janssen, Jeroen
    Traer, Elie
    Loo, Sun
    Narayan, Rupa
    Tovar, Natalia
    Kontro, Mika
    Ottmann, Oliver
    Naidu, Purushotham
    Kurtulus, Sema
    Makofske, Jessica
    Liao, Serena
    Mohammed, Anisa
    Sabatos-Peyton, Catherine A.
    Rinne, Mikael L.
    Borate, Uma
    Wei, Andrew H.
    BLOOD, 2020, 136
  • [8] STIMULUS MDS-US Trial in Progress: Evaluating Sabatolimab in Combination with Hypomethylating Agents (HMAs) in Patients with Intermediate-, High-, or Very High-Risk Myelodysplastic Syndromes (MDS)
    Zeidan, Amer M.
    DeZern, Amy
    Borate, Uma
    Kobata, Krissy
    Sadek, Islam
    Sabo, J. Randy
    Purkayastha, Das
    Ramos, Pedro Marques
    Sun, Haiying
    Lyons, Roger
    Garcia-Manero, Guillermo
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S348 - S349
  • [9] Efficacy and Safety of Sabatolimab (MBG453) in Combination with Hypomethylating Agents (HMAs) in Patients (Pts) with Very High/High-Risk Myelodysplastic Syndrome (vHR/HRMDS) and Acute Myeloid Leukemia (AML): Final Analysis from a Phase Ib Study
    Brunner, Andrew M.
    Esteve, Jordi
    Porkka, Kimmo
    Knapper, Steve
    Traer, Elie
    Scholl, Sebasttian
    Garcia-Manero, Guillermo
    Vey, Norbert
    Wermke, Martin
    Janssen, Jeroen
    Narayan, Rupa
    Loo, Sun
    Kontro, Mika
    Ottmann, Oliver
    Naidu, Purushotham
    Pelletier, Marc
    Han, May
    Lewandowski, Andrew
    Zhang, Na
    Mohammed, Anisha
    Rinne, Mikael L.
    Borate, Uma
    Wei, Andrew H.
    Tovar, Natalia
    BLOOD, 2021, 138
  • [10] Disease Characteristics and International Prognostic Scoring Systems (IPSS, IPSS-R, IPSS-M) in Adult Patients with Higher-Risk Myelodysplastic Syndromes (MDS) Participating in Two Randomized, Double-Blind, Placebo-Controlled Studies with Intravenous Sabatolimab Added to Hypomethylating Agents (HMA) (STIMULUS-MDS1 and MDS2)
    Santini, Valeria
    Platzbecker, Uwe
    Fenaux, Pierre
    Giagounidis, Aristoteles
    Miyazaki, Yasushi
    Sekeres, Mikkael A.
    Xiao, Zhijian
    Sanz, Guillermo
    Van Hoef, Marlies
    Ma, Fei
    Hertle, Sabine
    Ramos, Pedro Marques
    Zeidan, Amer M.
    BLOOD, 2022, 140 : 1340 - 1342
12345